Non-Small Cell Lung Cancer: Screening, Diagnosis, and Staging by Ferreira, J. et al.
Sa
n L
uc
as
 M
ed
ica
l, L
LC
Non-Small Cell Lung Cancer: Screening, Diagnosis, and
Staging
Joa˜o Pedro Ferreira1, Manuel Magalha˜es2, Estrela Rocha2 and Franklin Marques2
Affiliations: 1Internal Medicine Department, Centro Hospitalar do Porto, Porto, Portugal and 2Oncology Department, Centro Hospitalar do Porto, Porto, Portugal
(Submission Date: 26 November 2011; Accepted Date: 21 March 2012; Publication Date: 26 April 2012)
A B S T R A C T
Lung cancer is the leading cause of cancer deaths worldwide. Tobacco consumption is the primary cause of lung cancer, accounting
for more than 85%90% of all lung cancer deaths. Non-small cell lung cancer accounts for about 85% of all lung cancers.
Several studies have shown that low-dose helical CT of the lung detects more nodules and lung cancers, including early-stage cancers,
than does chest radiography. The National Lung Cancer Screening Trial results show that three annual rounds of low-dose CT screening
reduce mortality from lung cancer. Despite the great debate around lung cancer screening, recently the National Comprehensive Cancer
Network has come out in favor of lung cancer screening in an updated set of guidelines.
All patients who present with suspect lung cancer should have a complete and meticulous history and physical examination performed
to identify symptoms or physical findings suggestive of locally extensive or metastatic disease, assess pulmonary health status, identify
significant comorbidities, and assess overall health status.
Tissue sampling is required to confirm a diagnosis in all patients with suspected lung cancer. Non-surgical approaches, surgical
approaches, or both may be used to obtain a tissue sample. Evaluation of the mediastinal lymph nodes is a key step in the further staging
of the patient. The best way of evaluating mediastinal lymph nodes is still a matter of debate.
The tumor node metastasis (TNM) International Staging System provides useful prognostic information and is used to stage all patients
with non-small cell lung cancer.
Recent trials added new data on screening and diagnostic approach. Those data will be reviewed in this paper.
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INTRODUCTION
Lung cancer is the leading cause of cancer deaths world-
wide.1 Tobacco consumption is the primary cause of lung
cancer, accounting for more than 85%90% of all lung
cancer deaths. While tobacco smoking remains the primary
cause of lung cancer worldwide, more than 60% of new lung
cancer occur in former smokers (smoked]100 cigarettes
per lifetime, quit]1 year) or never smokers (smokedB100
cigarettes per lifetime). Moreover, one in five women and
one in 12 men diagnosed with lung cancer have never
smoked. Environmental tobacco smoke or secondhand
smoke, occupational exposure to asbestos, arsenic, nickel,
mustard gas, bischloromethyl ether, hexavalent chromium,
polycyclic aromatic hydrocarbons, and ionizing radiation are
also established risk factors for lung cancer.2 Lung cancer
susceptibility and risk also are increased in inherited cancer
syndromes caused by rare germ-line mutations in p53,3
retinoblastoma,4 and other genes.5,6
The two major forms of lung cancer are non-small cell
lung cancer (NSCLC, about 85% of all lung cancers) and
small-cell lung cancer (about 15%). Despite advances in early
detection and standard treatment, NSCLC is often diagnosed
at an advanced stage and has a poor prognosis. NSCLC
can be divided into three major histologic subtypes:
(1) squamous-cell carcinoma, (2) adenocarcinoma, and
(3) large-cell lung cancer. Smoking causes all types of lung
cancer but is most strongly linked with small-cell lung cancer
and squamous-cell carcinoma; adenocarcinoma is the most
common type in patients who have never smoked.79
Recent trials added new data on screening and diagnostic
approach. Those data will be reviewed here.
EARLY DETECTION AND SCREENING
For a screening program to be successful, the burden of
the disease in the population must be high, effective treatment
must be available, the test must be low risk, reproducible,
accessible, cost-effective, and both sensitive and specific,
and there should be an effective treatment or intervention
for patients identified through early detection, with evidence
of early treatment leading to better outcomes than late
treatment.
The large majority of NSCLC patients present with symp-
toms in a late advanced stage, and diagnosis occurs mostly
in locally advanced or metastatic disease with a very poor
rate of cure. The issue of lung cancer screening has
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consequently a strong rationale, to increase the detection of
early NSCLC potentially cured by surgery.
Although effective mass screening of high-risk groups
could potentially be of benefit, randomized trials of screening
with the use of chest radiography with or without cytologic
analysis of sputum specimens have shown no reduction in
lung-cancer mortality.10
Advances in multidetector computed tomography (CT),
however, have made high-resolution volumetric imaging
possible in a single breath hold at acceptable levels of radiation
exposure.11 Several studies10,1217 have shown that low-dose
helical CT of the lung detects more nodules and lung cancers,
including early-stage cancers, than does chest radiography.
The National Lung Cancer Screening Trial (NLST),18
a large prospective randomized trial funded by the National
Cancer Institute (NCI), to determine whether screening with
low-dose CT, as compared with chest radiography (CXR),
would reduce mortality from lung cancer among high-risk
persons. In this trial 53,454 participants, between 55 and
74 years of age and a history of heavy smoking, were
enrolled. Participants were randomly assigned to undergo
three annual screenings with either low-dose CT (26,722
participants) or single-view posterioanterior chest radiogra-
phy (26,732 participants). Non-calcified nodules measuring 4
mm were considered to be positive, as were abnormalities
such as effusions and adenopathy. During median follow-up
of 6.5 years, lung cancerspecific mortality was significantly
lower in the CT group than in the CXR group*relative
reduction of 20.0% (95% CI, 6.826.7; P.004). Deaths
attributed to invasive diagnostic procedures and cancer
treatments were considered lung cancerrelated deaths. The
number needed to screen to prevent one lung cancer death
was about 320. False-positive screenings were common: 39%
of participants in the CT group and 16% in the CXR group
had at least one positive screen, and 95% of those results
were false-positives. The NLST results show that three annual
rounds of low-dose CT screening reduce mortality from lung
cancer. However, many questions remain. For example,
will radiologists generally be able to duplicate the perfor-
mance of NLST study radiologists? In the community, will
low-dose CT (as opposed to standard-dose CT) be readily
available and will evaluation and follow-up of screen-positive
patients maximize benefit and minimize harm? Given the
high false-positive rate, how should we weigh the costs and
morbidity of screening and its sequelae? Because of many
pending questions, one should wait for further information
before endorsing screening.19,20 For those patients who want
to be screened, physicians need to discuss the possible
risks and benefits of screening. While lung cancers may be
found, patients are at risk for more radiation exposure and
false-positive results. The latter can result in multiple follow-
up CTs and possible invasive procedures, with potential
added costs, anxiety, and morbidity and mortality rates.2
Despite the great debate around lung cancer screening, which
is a complex and controversial topic, recently the National
Comprehensive Cancer Network (NCCN) has come out in favor
of lung cancer screening in an updated set of guidelines.21 It
recommends the use of helical low-dose CT screening for
selected patients at high risk for the disease*risk assessment
and screening modalities are discussed in the guidelines.
CLINICAL MANIFESTATIONS
All patients who present with suspect NSCLC should have a
complete and meticulous history and physical examination
performed to identify symptoms or physical findings sugges-
tive of locally extensive or metastatic disease, assess pulmon-
ary health status, identify significant comorbidities, and
assess overall health status. Each impacts the therapeutic
options, patient’s ability to tolerate treatment, and disease
course in ways that are independent of the disease stage.20,22
Most symptoms and signs (eg, cough, hemoptysis, and
postobstructive pneumonia) are non-specific. However, some
signs and symptoms, such as weight loss, bone pain, dyspha-
gia, neurologic abnormalities, superior vena cava syndrome,
pericardial effusion, enlarged supraclavicular and scalene
lymph nodes, and hepatomegaly or right upper quadrant
pain, may suggest extensive disease.
NSCLC may cause paraneoplastic syndromes. These are
characterized by endocrinopathy, neurologic disorders, meta-
bolic abnormalities, hematologic disease, or skeletal syn-
dromes and may be the presenting finding or the first sign of
recurrence. In addition, paraneoplastic syndromes may mimic
metastatic disease and, unless detected, lead to inappropriate
palliative rather than curative treatment. In some cases, the
pathophysiology of the paraneoplastic syndrome is known,
particularly when a hormone with biologic activity is secreted
by the tumor or an immunologic-mediated mechanism is
involved. Often the paraneoplastic syndrome may be relieved
with successful treatment of the tumor.2 A detailed description
of paraneoplastic syndromes is beyond the scope of this review.
DIAGNOSTIC ASSESSMENT AND STAGING
INVESTIGATIONS
Initial evaluation must include performance status, CT of
the neck, chest and upper abdomen, including adrenals,
complete blood count and platelets, chemistry profile,
smoking cessation program (if needed), and pathology review
(specific mutations may be a therapy target).23
Tissue sampling is required to confirm a diagnosis in all
patients with suspected lung cancer. Pathologic evaluation is
performed to classify the histologic type of the lung cancer,
determine the extent of invasion, determine whether it is
primary lung cancer or metastatic disease, establish the
cancer involvement status of the surgical margins, and do
molecular diagnostic studies to determine whether certain
gene mutations are present (eg, EGFR mutations).
There are several options for sampling a primary tumor,
including: (1) conventional flexible bronchoscopy with forceps
biopsy, (2) blind transbronchial fine-needle aspiration,
(TBNA), (3) image-guided percutaneous fine-needle aspiration
or core-needle biopsy, (4) surgical biopsy, (5) endobronchial
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ultrasound (EBUS)-guided biopsy, and/or (6) transesophageal
endoscopic ultrasound-guided biopsy (EUS).
In patients with suspected metastatic disease, a diagnosis
may be confirmed by percutaneous biopsy of a soft tissue
mass, lymph node, lytic bone lesion, bone marrow, pleural
or liver lesion, or an adequate cell sample obtained from
a malignant pleural effusion. In patients with a suspected
malignant pleural effusion, if the initial thoracocentesis is
negative, a repeat thoracocentesis is recomended.2 Series
examining the diagnostic rate for malignancy of pleural
cytology have reported a mean sensitivity of 60% (range
40%87%).2427 In patients suspected of having lung cancer
with an accessible pleural effusion, if the pleural fluid
cytology finding is negative (after at least two thoracocent-
esis), thoracoscopy is recommended as the next step if
establishing the cause of the pleural effusion is thought to
be clinically important. Thoracoscopic biopsy of the pleura is
safe and can provide a definitive diagnosis with a high degree
of accuracy and minimal risk to the patient. The reported
sensitivity rate ranges between 80% and 99%. However,
percutaneous, closed pleural biopsy is reported to be
diagnostic for malignancy in only 50% of cases.28
The diagnostic yield of any biopsy depends on several factors
including location and size of the tumor, tumor type, and
technical aspects of the procedure. In general, central lesions
are more readily diagnosed by bronchoscopic examination,
while peripheral lesions are more amenable to transthoracic
biopsy.29 Bronchoscopic specimens include bronchial brush,
bronchial wash, bronchioloalveolar lavage, and transbronchial
biopsy (forceps biopsy, TBNA, and EBUS). Overall sensitivity
for bronchoscopic methods is 85%90%. Transthoracic FNA
specimens have also great sensitivity (70%95%).2831
For patients who have multiple comorbidities or contra-
indications to invasive biopsy, sputum cytology should be
considered, especially for patients with centrally located
tumors, but pooled sensitivity is low (66%).28
Non-surgical approaches, surgical approaches, or both may
be used to obtain a tissue sample from patients with suspected
lymph node metastasis.23 Depending on the location, lymph
node sampling may occur via EBUS, EUS, or blind biopsy. In
patients with palpable lymph nodes, a needle biopsy or needle
aspiration may be used to obtain a tissue sample. Successful
application of the non-surgical approaches may eliminate the
need for a surgical staging proced re.
Evaluation of the mediastinal lymph nodes is a key step in
the further staging of the patient. To detect mediastinal
metastases, patients are routinely investigated with CT and
positron emission tomography (PET), followed by mediastinal
tissue staging for enlarged (]10 mm) or PET-positive
intrathoracic nodes,32,33 as imaging alone is inaccurate to
replace invasive lymph node staging on tissue specimens.3437
In addition, the visual location of intrathoracic lymph nodes
with PET is not always unequivocal because of the low
spatial resolution of the PET images.3840 Integrated PET/CT
scans theoretically overcome this problem because of
the co-acquisition of CT and PET images, resulting in
so-called fusion images. However, no difference in accuracy
was noted when integrated PET/CT scans were compared
with CT scans alone.41 A prospective study assessed the
accuracy of the integrated PET/CT scan in the nodal staging
of NSCLC and evaluated if tissue-confirmed lymph node
staging by surgery or echo-endoscopy could be avoided.34
This study found that integrated PET/CT scanning has an
overall accuracy, which is too low to replace invasive
intrathoracic lymph node staging. Another study found that
integrated PET/CT provides low sensitivity and accuracy in
intrathoracic nodal staging of NSCLC patients and underscore
the continued need for histologic diagnosis.42
Undetected preoperatory mediastinal metastases are a major
cause of unnecessary thoracotomies, occurring in 28% of
patients.36 Unnecessary thoracotomies result in suboptimal
treatment, significantly impaired functional health status, and
avoidable mortality.43,44
Mediastinal tissue staging is classically performed by
mediastinoscopy, a surgical diagnostic procedure with a
sensitivity of approximately 80%.33 Mediastinal lymph nodes
can also be sampled under real-time ultrasound control from
either the esophagus (EUS)45 or the airways (EBUS).46
Combined EUS and EBUS can reach almost all mediastinal
nodal stations with a reported sensitivity of 93% (CI95%, 81%
99%) and 97% specificity (CI95%, 91%99%) for establishing
the presence of mediastinal disease in lung cancer patients.47
Current lung cancer staging guidelines acknowledge endoso-
nography as a minimally invasive alternative to surgical
staging (mediastinoscopy) to detect nodal disease,21 reducing
the need for surgical staging in up to two thirds of
patients.48,49 A study was designed to examine the hypothesis
that minimally invasive combined endoscopic procedures were
as good as or even better than surgical staging (mediastino-
scopy) for the evaluation of mediastinal lymph nodes in
patients with lung cancer.49 In this study, patients were
eligible for mediastinal nodal sampling if they had mediastinal
nodes with short axis ]10 mm on CT or PET-positive
mediastinal or hilar nodes or centrally located lung tumor.
Patients with proven distant metastasis, irresectable disease
(as judged by the thoracic surgeon on the available imaging),
or small peripheral lung tumors without evidence of enlarged
or PET-positive intrathoracic nodes were not considered for
eligibility. The primary outcome was sensitivity for mediast-
inal nodal metastases. Secondary outcomes were rates of
unnecessary thoracotomy and complications. Two hundred
forty-one patients were randomized, 118 to surgical staging
and 123 to endosonography, of whom 65 also underwent
surgical staging. Nodal metastases were found in 41 patients
(35%) by surgical staging versus 56 patients (46%) by
endosonography (P.11) and in 62 patients (50%) by
endosonography followed by mediastinoscopy (P.02). This
study has shown that commencing mediastinal nodal staging
with endosonography significantly improves the detection of
nodal metastases and reduces the rate of unnecessary
thoracotomies compared with mediastinoscopy alone, in
patients with resectable NSCLC. This combined approach,
with mediastinoscopy reserved for those patients with negative
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Table 1. TNM Staging System for Lung Cancer (7th Edition)
Primary tumor (T)
T1 Tumor 53 cm diameter, surrounded by lung or visceral pleura, without invasion more proximal than lobar bronchus
T1a Tumor 52 cm in diameter
T1b Tumor 2 cm but 53 cm in diameter
T2 Tumor 3 cm but 57 cm, or tumor with any of the following features:
1. Involves main bronchus, ]2 cm distal to carina
2. Invades visceral pleura
3. Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung
T2a Tumor 3 cm but 55 cm
T2b Tumor 5 cm but 57 cm
T3 Tumor 7 cm or any of the following:
1. Directly invades any of the following: chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, main bronchus
B2 cm from carina (without involvement of carina)
2. Atelectasis or obstructive pneumonitis of the entire lung
3. Separate tumor nodules in the same lobe
T4 Tumor of any size that invades the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, or
with separate tumor nodules in a different ipsilateral lobe
Regional lymph nodes (N)
N0 No regional lymph node metastases
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct
extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
M1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural or pericardial effusion
M1b Distant metastasis (in extrathoracic organs)
Stage groupings
Stage IA T1a-T1b N0 M0
Stage IB T2a N0 M0
Stage IIA T1a, T1b, T2a N1 M0
T2b N0 M0
Stage IIB T2b N1 M0
T3 N0 M0
Stage IIIA T1a, T1b, T2a, T2b N2 M0
T3 N1, N2 M0
T4 N0, N1 M0
Stage IIIB T4 N2 M0
Any T N3 M0
Stage IV Any T Any N M1a or M1b
Note: Adapted from: Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groups in
the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:70616.
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findings on EBUS/EUS resulted in superior sensitivity and
negative predictive value over mediastinoscopy alone. This
benefit was not associated with a greater rate of complica-
tions. These results are consistent with findings of other
studies.50
Missing mediastinal nodal metastases during preoperative
surgical staging results in patients needlessly undergoing
thoracotomy. Because almost all mediastinal nodes can be
covered, a combined endosonography (EBUS/EUS) investiga-
tion could be superior to mediastinoscopy staging in the
detection of nodal disease. Furthermore, endosonography
does not require general anesthesia, is preferred by patients,51
and is considered cost-effective52 compared with surgical
staging.
Even though this emerging technology of endoscopic study
can have excellent results for predicting both positive and
negative values, referral centers with highly skilled inter-
ventionalists are required to provide these good results.53
Mediastinal node evaluation is straightforward when pa-
tients have a positive PET and/or CT scan (]10 mm).
Noteworthy, mediastinal node evaluation is also appropriate
for patients with T2/3 and central T1 lesions, even if the PET/
CT scan do not suggest mediastinal node involvement.23,54,55
In other hand, because of the low prior probability of lymph
node involvement in patients with peripheral T1, clinical No
lesions, some authors do not use routine mediastinoscopy in
these patients.56
Regarding adrenal nodules, it should be noted that adrenal
gland nodules or masses may be found by CT in 3%4% of
patients.5759 In patients with lung cancer, most adrenal
nodules are benign adenomas (fewer than half are metastasis).
All adrenal lesions in patients with suspected lung cancer
require direct evaluation if it will determine the disease stage.
A malignant adrenal nodule is considered distant metastasis.
Conventional CT and MRI imaging of adrenal lesions permits
initial characterization of adrenal nodules. Protocols that
measure the washout of attenuation following the adminis-
tration of intravenous contrast significantly improve the
sensitivity and specificity of CT for characterizing adrenal
lesions.6062 PET imaging may also improve the sensitivity,
specificity, and accuracy of adrenal gland imaging.63
An adrenal gland biopsy should be performed if confirma-
tion of the adrenal pathology will determine the disease stage
and treatment options. Image-guided fine needle biopsy is
the most common approach.63
STAGING SYSTEM
The TNM International Staging System provides useful
prognostic information and is used to stage all patients with
NSCLC. The various T (tumor size), N (regional node
Figure 1. Detail of mediastinal diagnosis and staging.
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involvement), and M (presence or absence of distant metas-
tasis) are combined to form different stage groups. The 7th
edition of the TNM staging system is the most recent version
(Table 1).64
Four types of staging can be performed in patients with
NSCLC. All are based on the TNM staging system:
1. The clinical-diagnostic stage (the focus of this review)
is based upon medical history, physical examination,
laboratory testing, physiologic evaluation, radiologic
testing, tissue sampling, and any other investigation
undertaken prior to primary therapy. It is assigned the
prefix c (p.e. cT3N2M0).
2. The surgical-pathologic evaluation is based on the
clinical-diagnostic stage plus histopathologic data
from the resected tumor. It provides confirmation of
the T descriptor, N descriptor, and histologic type.
In addition, it takes into account the histologic grade,
resection margins, and presence or absence of lym-
phovascular invasion. The surgical-pathologic stage is
assigned the prefix p (p.e. pT3N2M0).
3. A retreatment stage is assigned if there is recurrence of
disease and a new treatment program is planned.
4. An autopsy stage is recorded when a patient dies and
has a postmortem examination performed.
Patients who may be a candidate for surgical resection of
the NSCLC should undergo complete pulmonary function
testing and consultation with a cardiothoracic surgeon.65
SUMMARY
When a patient presents with suspected NSCLC, the
diagnosis should be confirmed and both the histologic type
and disease stage should be determined.
All patients should undergo a detailed history, CT of the
neck, chest, and upper abdomen, including adrenals, com-
plete blood count and platelets, chemistry profile, smoking
cessation program (if needed), and pathology review.
Undetected mediastinal metastases are a major cause of
unnecessary thoracotomies. Unnecessary thoracotomies re-
sult in suboptimal treatment, significantly impaired func-
tional health status, and avoidable mortality. To detect
mediastinal metastases, patients are routinely investigated
with CT and PET, followed by mediastinal tissue staging for
enlarged (]10 mm) or PET-positive intrathoracic nodes.
However, integrated PET/CT scanning has an overall accu-
racy, which is too low to replace invasive intrathoracic lymph
node staging. Mediastinal tissue staging is classically per-
formed by mediastinoscopy. Current lung cancer staging
guidelines acknowledge endosonography as a minimally
invasive alternative to surgical staging (mediastinoscopy) to
detect nodal disease. A combined endosonography investiga-
tion could be superior to mediastinoscopy staging in the
detection of nodal disease (Figure 1).
Staging is based upon the TNM staging system for NSCLC
(Table 1)
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